Why the study?
What is the evidence base and optimum dosing for antidotes to coumarins, isoniazid, methotrexate, and thyroxine in overdose?
What is the evidence base and optimum dosing for antidotes to coumarins, isoniazid, methotrexate, and thyroxine in overdose?
This review highlights the need for further studies to determine the optimal dosing of antidotes for coumarin, isoniazid, and methotrexate overdoses.
Mechanism-based antidote use guides current management of these overdoses; leaves open optimal dosing via dedicated studies.
Some toxins cause their effects by affecting physiological processes that are fundamental to cell function or cause systemic effects as a result of cellular interaction. This review focuses on four examples, coumarin anticoagulants, isoniazid, methotrexate and thyroxine from the context of management of overdose as seen in acute general hospitals. The current basic clinical pharmacology of the toxin, the clinical features in overdose and evidence base for specific antidotes are discussed. The treatment for this group is based on an understanding of the toxic mechanism, but studies to determine the optimum dose of antidote are still required in all these toxins except thyroxine, where treatment dose is based on symptoms resulting from the overdose.
No takes yet. Share an insight, caveat, or question.
Bateman et al. (2015) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: